CDT Equity Welcomes Interim U.S. Policy Supporting Compounded Peptide Access

• CDT Equity today welcomed a US peptide compounding policy as supportive of its investment in Pep'd, a US peptide and telehealth company.
• The HHS policy limits enforcement against qualifying providers compounding six specified peptides, subject to regulatory conditions.
• CEO James Bligh called the policy a positive development for the investment, noting it remains interim; the covered peptides lack FDA approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CDT Equity Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610300832PRIMZONEFULLFEED9856887) on October 30, 2026, and is solely responsible for the information contained therein.